TD Cowen raised the firm’s price target on DarioHealth (DRIO) to $11 from 60c and keeps a Hold rating on the shares. The company updated its model following Q3 results which showed its revenue weakness continuing but noting its strong pipeline could lead to a recovery in 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRIO:
- DarioHealth price target lowered to $16 at Stifel after reverse stock split
- DarioHealth Reports Q3 2025 Financial Results
- DarioHealth’s Earnings Call: Optimism Amid Revenue Shift
- DarioHealth’s Mixed Financial Outlook: Hold Rating Amidst Revenue Challenges and Future Growth Prospects
- DarioHealth reports Q3 EPS ($2.96), consensus ($2.42)